Not independent
Tenure on this board
10.9 yrs
Also a director at
Autonomix Medical Inc (AMIX)
8 nominees · 3 ballot items.
Three management proposals are up for a vote at the Moleculin Biotech special meeting: (1) Nasdaq Proposal to approve issuance of up to 2,610,823 shares upon exercise of warrants issued December 11, 2025; (2) Name Change Proposal to amend the Certificate of Incorporation to change the company name from Moleculin Biotech, Inc. to Moleculin Inc.; and (3) Adjournment Proposal to adjourn the meeting to solicit additional proxies if necessary.
Approve the issuance of up to 2,610,823 shares of common stock upon the exercise of certain warrants issued on December 11, 2025, to comply with Nasdaq Listing Rule 5635(d).
Approve an amendment to the Amended and Restated Certificate of Incorporation to change the company name from Moleculin Biotech, Inc. to Moleculin Inc.
Approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Proposal or the Name Change Proposal.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | SABBY MANAGEMENT, LLC | 1.41% | 75,021 | $172K |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 0.49% | 26,038 | $60K |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 0.26% | 13,869 | $32K |
| 4 | HRT FINANCIAL LP | 0.26% | 13,739 | $31K |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 0.12% | 6,291 | $14K |
| 6 | VANGUARD FIDUCIARY TRUST CO | 0.11% | 6,072 | $14K |
| 7 | Rockefeller Capital Management L.P. | 0.08% | 4,421 | $10K |
| 8 | UBS Group AG | 0.06% | 3,409 | $8K |
| 9 | Tower Research Capital LLC (TRC | 0.03% | 1,835 | $4K |
| 10 | BlackRock, Inc. | 0.01% | 491 | $1K |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.